Literature DB >> 24296361

Gene expression profile in fibroblasts of Huntington's disease patients and controls.

Eleonora Marchina1, Silvia Misasi2, Andrea Bozzato2, Sergio Ferraboli2, Chiara Agosti3, Luca Rozzini3, Giuseppe Borsani2, Sergio Barlati2, Alessandro Padovani3.   

Abstract

Huntington's disease is an inherited disorder caused by expanded stretch of consecutive trinucleotides (cytosine-adenosine-guanine, CAG) within the first exon of the huntingtin (HTT) gene on chromosome 4 (p16.3). The mutated huntingtin (mHTT) gains toxic function, probably through mechanisms that involve aberrant interactions in several pathways, causing cytotoxicity. Pathophysiology of disease involves several tissues; indeed it has been shown that there is a broad toxic effect of mHTT in the peripheral tissue of patients with HD, not only in the central nervous system. In this study we compared gene expression profiles (GEP) of HD fibroblasts and matched controls using microarray technology. We used RT-PCR to test the consistency of the microarray data and we found four genes up-regulated in HD patients with respect to control individuals. The genes appear to be involved in different pathways that have been shown to be perturbed even in HD models and patients. Although our study is preliminary and has to be extended to a larger cohort of HD patients and controls, nevertheless it shows that gene expression profiles seem to be altered in the fibroblasts of HD patients. Validation of the differential expressions at the protein level is required to ascertain if this cell type can be considered a suitable model for the identification of HD biomarkers.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomarkers; Gene expression profile; Human fibroblasts; Huntingtin; Huntington's disease; Neurodegeneration; PolyQ

Mesh:

Substances:

Year:  2013        PMID: 24296361     DOI: 10.1016/j.jns.2013.11.014

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  14 in total

1.  Exploring Genetic Factors Involved in Huntington Disease Age of Onset: E2F2 as a New Potential Modifier Gene.

Authors:  Leire Valcárcel-Ocete; Gorka Alkorta-Aranburu; Mikel Iriondo; Asier Fullaondo; María García-Barcina; José Manuel Fernández-García; Elena Lezcano-García; José María Losada-Domingo; Javier Ruiz-Ojeda; Amaia Álvarez de Arcaya; José María Pérez-Ramos; Raymund A C Roos; Jørgen E Nielsen; Carsten Saft; Ana M Zubiaga; Ana Aguirre
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

Review 2.  Oligonucleotide-based strategies to combat polyglutamine diseases.

Authors:  Agnieszka Fiszer; Wlodzimierz J Krzyzosiak
Journal:  Nucleic Acids Res       Date:  2014-05-21       Impact factor: 16.971

Review 3.  Transcription, epigenetics and ameliorative strategies in Huntington's Disease: a genome-wide perspective.

Authors:  Luis M Valor
Journal:  Mol Neurobiol       Date:  2014-05-01       Impact factor: 5.590

4.  miR-196a Ameliorates Cytotoxicity and Cellular Phenotype in Transgenic Huntington's Disease Monkey Neural Cells.

Authors:  Tanut Kunkanjanawan; Richard L Carter; Melinda S Prucha; Jinjing Yang; Rangsun Parnpai; Anthony W S Chan
Journal:  PLoS One       Date:  2016-09-15       Impact factor: 3.240

5.  Mitochondrial alterations accompanied by oxidative stress conditions in skin fibroblasts of Huntington's disease patients.

Authors:  Paulina Jędrak; Paweł Mozolewski; Grzegorz Węgrzyn; Mariusz R Więckowski
Journal:  Metab Brain Dis       Date:  2018-08-17       Impact factor: 3.584

6.  Genistein induces degradation of mutant huntingtin in fibroblasts from Huntington's disease patients.

Authors:  Karolina Pierzynowska; Lidia Gaffke; Zuzanna Cyske; Grzegorz Węgrzyn
Journal:  Metab Brain Dis       Date:  2019-03-09       Impact factor: 3.584

7.  Evaluating the SERCA2 and VEGF mRNAs as Potential Molecular Biomarkers of the Onset and Progression in Huntington's Disease.

Authors:  Federica Cesca; Elisa Bregant; Borut Peterlin; Maja Zadel; Giorgia Dubsky de Wittenau; Gabriele Siciliano; Roberto Ceravolo; Lucia Petrozzi; Giada Pauletto; Lorenzo Verriello; Paolo Bergonzi; Giuseppe Damante; Giovanni Barillari; Bruno Lucci; Francesco Curcio; Incoronata Renata Lonigro
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

8.  Cardiac Dysfunction in the BACHD Mouse Model of Huntington's Disease.

Authors:  Analyne M Schroeder; Huei Bin Wang; Saemi Park; Maria C Jordan; Fuying Gao; Giovanni Coppola; Michael C Fishbein; Kenneth P Roos; Cristina A Ghiani; Christopher S Colwell
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

9.  Mitochondrial Bioenergetics Is Altered in Fibroblasts from Patients with Sporadic Alzheimer's Disease.

Authors:  María J Pérez; Daniela P Ponce; Cesar Osorio-Fuentealba; Maria I Behrens; Rodrigo A Quintanilla
Journal:  Front Neurosci       Date:  2017-10-06       Impact factor: 4.677

10.  Juvenile Huntington's Disease Skin Fibroblasts Respond with Elevated Parkin Level and Increased Proteasome Activity as a Potential Mechanism to Counterbalance the Pathological Consequences of Mutant Huntingtin Protein.

Authors:  Azzam Aladdin; Róbert Király; Pal Boto; Zsolt Regdon; Krisztina Tar
Journal:  Int J Mol Sci       Date:  2019-10-26       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.